Ninety One UK 13F: Cuts Abbott Laboratories (ABT) Stake by $68M

Ninety One UK scaled back its investment in Abbott Laboratories NYSE: ABT, cutting its holdings by 690,686 shares during the period. According to a Form 13F filed with the Securities and Exchange Commission on October 15, 2026, the fund's stake decreased by 27.8% to 1,793,214 shares. The remaining position was valued at approximately $177.2 million when reported. Keep in mind that 13F filings are backward-looking and reflect holdings as of the close of the quarter, so they might not capture the fund's current stance. This move follows recent adjustments by the firm, including trimmed stakes in other major equities.

What Changed in Ninety One UK's Abbott Laboratories Position

The fund held 2,483,900 shares of the medical devices maker prior to the adjustment. By selling off 690,686 shares, Ninety One UK brought its total down to 1,793,214 shares. The 27.8% reduction leaves the firm with a smaller footprint in the healthcare giant, valued at $177,223,346.

Other Institutional Activity in Abbott Laboratories

Blackrock Inc. grew its holdings by 6,876,428 shares, ending with 152,563,476 shares worth about $16.0 billion. Vanguard Capital Management LLC grew its holdings by 801,938 shares, ending with 113,750,994 shares worth about $11.9 billion. State Street Corporation grew its holdings by 1,352,749 shares, ending with 80,926,234 shares worth about $8.5 billion. Charles Schwab Investment Management, Inc. grew its holdings by 14,173,548 shares, ending with 59,674,507 shares worth about $6.3 billion.

Abbott Laboratories Stock Up 2.3%

Abbott shares recently traded around $104.70 as of October 16, 2026. The stock sits below its 50-day moving average of $105.93 and above its 200-day moving average of $102.91. It has traded between a 52-week low of $81.97 and a 52-week high of $132.03.

Recent Earnings

Abbott Laboratories posted trailing twelve-month revenue of $46.58 billion alongside diluted earnings of $3.10 per share. The company reported a net profit margin of 11.6% and a return on equity of 10.6%. Its next quarterly earnings release is scheduled for October 21, 2026.

Dividend

The company pays an annual dividend yielding 2.41% with a payout ratio of 78.7%.

Insider Buying and Selling at Abbott Laboratories

Director John G. Stratton bought 2,000 shares on May 7, 2026, at an average price of $86.82 for a total value of $173,640. Officer Louis H Morrone sold 5,850 shares on August 11, 2026, at an average price of $109.83 for a total of $642,506. Chief Executive Officer Robert B. Ford sold 398,832 shares on August 25, 2026, valued at $46,204,798. Officer John A. Mccoy Jr sold 27 shares on September 2, 2026, at an average price of $109.54 for a total of $2,958.

Analysts Set New Price Targets

On August 21, 2026, TD Cowen maintained its Buy rating on the stock and raised its price target from $115.00 to $135.00. TD Cowen reiterated its Buy rating with a $135.00 target on August 25, 2026, and again on September 8, 2026. Rothschild & Co upgraded the stock to Buy on October 2, 2026, raising its target from $119.00 to $127.00. Barclays initiated coverage with an Overweight rating and a $120.00 target on October 7, 2026. Across 26 analyst opinions, the stock holds a consensus strong buy rating with a mean price target of $120.72.

About Abbott Laboratories

Abbott Park, Illinois-based Abbott Laboratories creates and sells health care products around the world. The company operates through four primary divisions, covering established pharmaceutical items, diagnostic tools, nutritional goods, and advanced medical devices.

Bottom Line

Ninety One UK's decision to cut its stake comes right before the company's next earnings report on October 21, 2026. Investors will look to that report for fresh details on segment performance and profit margins.